BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31004581)

  • 1. LncRNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma through epigenetically silencing CDKN1B(p27) via EZH2.
    Xu K; Zhang Z; Qian J; Wang S; Yin S; Xie H; Zhou L; Zheng S
    Exp Cell Res; 2019 Jul; 380(2):198-204. PubMed ID: 31004581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
    Lei T; Zhu X; Zhu K; Jia F; Li S
    Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma.
    Li Y; Zhuang W; Huang M; Li X
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1051-1057. PubMed ID: 31097223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer.
    Xu TP; Wang WY; Ma P; Shuai Y; Zhao K; Wang YF; Li W; Xia R; Chen WM; Zhang EB; Shu YQ
    Oncogene; 2018 Sep; 37(36):5020-5036. PubMed ID: 29789713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis.
    Hu W; Feng H; Xu X; Huang X; Huang X; Chen W; Hao L; Xia W
    Cancer Med; 2020 Aug; 9(15):5620-5631. PubMed ID: 32558350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA SOX21-AS1 is associated with progression of hepatocellular carcinoma and predicts prognosis through epigenetically silencing p21.
    Wei C; Wang H; Xu F; Liu Z; Jiang R
    Biomed Pharmacother; 2018 Aug; 104():137-144. PubMed ID: 29772433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
    Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
    J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21.
    Ren Z; Hu Y; Li G; Kang Y; Liu Y; Zhao H
    Biomed Pharmacother; 2019 Sep; 117():109104. PubMed ID: 31228799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA HOXD-AS1 aggravates osteosarcoma carcinogenesis through epigenetically inhibiting p57 via EZH2.
    Gu W; Zhang E; Song L; Tu L; Wang Z; Tian F; Aikenmu K; Chu G; Zhao J
    Biomed Pharmacother; 2018 Oct; 106():890-895. PubMed ID: 30119259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma.
    Xu F; Li CH; Wong CH; Chen GG; Lai PBS; Shao S; Chan SL; Chen Y
    Cancer Res; 2019 Apr; 79(7):1305-1317. PubMed ID: 30718359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA (lncRNA) FOXD2-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Regulating MiR-185/AKT Axis.
    Chen Z; Zhang Z; Zhao D; Feng W; Meng F; Han S; Lin B; Shi X
    Med Sci Monit; 2019 Dec; 25():9618-9629. PubMed ID: 31841454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway.
    Sun J; Guo Y; Bie B; Zhu M; Tian H; Tian J; Li J; Yang Y; Ji F; Kong G; Li Z
    J Cell Biochem; 2020 Jan; 121(1):443-457. PubMed ID: 31231887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lncRNA
    Zhou N; Li S; Wu D; Zhang F; Tang F; Li Y
    DNA Cell Biol; 2021 Oct; 40(10):1278-1289. PubMed ID: 34558987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
    FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA DCST1-AS1 functions as a competing endogenous RNA to regulate FAIM2 expression by sponging miR-1254 in hepatocellular carcinoma.
    Chen J; Wu D; Zhang Y; Yang Y; Duan Y; An Y
    Clin Sci (Lond); 2019 Jan; 133(2):367-379. PubMed ID: 30617187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.